EML4 and non-small cell lung carcinoma: Although the ALK inhibitor is an effective drug for the treatment of EML4-ALK-positive NSCLC (10,11), the current patient was not initially evaluated for the presence of the translocation, as the indication was not included in clinical practice guidelines at the time of relapse (January 2010).